Dashboard
Manage Tickers

BLRX

Nasdaq biolinerx.com


$ 0.70 ()    

Wednesday, 05-Jun-2024 11:30:48 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ 3.42 (0.75 %)
DIA $ 398.57 $ -0.78 (-0.2 %)
SPY $ 530.36 $ 1.04 (0.2 %)
TLT $ 91.26 $ 0.21 (0.23 %)
GLD $ 225.37 $ 1.13 (0.52 %)
$ 0.69875
$ 0.70
$ 0.00 x 0
$ 0.00 x 0
$ 0.70 - $ 0.70
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target
HC Wainwright & Co. Reiterates Buy on BioL...
06/03/2024 16:36:16

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

biolinerx-announces-multi-center-phase-1-trial-sponsored-by-st-jude-childrens-research-hospital-to-evaluate-motixafortide-for-cd34-hematopoietic-stem-cell-mobilization-for-gene-therapy-applications-in-sickle-cell-disease
BioLineRx Announces Multi-Center Phase 1 T...
05/30/2024 11:11:30

hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target
HC Wainwright & Co. Reiterates Buy on BioL...
05/29/2024 14:24:02

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

biolinerx-shares-are-trading-higher-the-company-reported-q1-financial-results
BioLineRx shares are trading higher. The c...
05/28/2024 11:44:00

biolinerx-says-cash-cash-equivalents-and-short-term-bank-deposits-of-282m-will-be-sufficient-to-fund-operations-as-currently-planned-into-2025
BioLineRx Says Cash, Cash Equivalents, And...
05/28/2024 11:06:15

The company says this amount does not include $6.0 million in gross proceeds received from a registered direct offering and a $...

bioline-rx-q1-2024-gaap-eps-000-may-not-be-comparable-to-029-estimate-sales-6855m-may-not-be-comparable-to-340000k-estimate
BioLine Rx Q1 2024 GAAP EPS $(0.00) May No...
05/28/2024 11:03:38

biolinerx-discloses-abstract-on-pilot-study-data-from-phase-2-combination-clinical-trial-evaluating-motixafortide-in-first-line-pancreatic-cancer-at-american-society-of-clinical-oncology-2024-annual-meeting
BioLineRx Discloses Abstract On Pilot Stud...
05/24/2024 11:02:58

New analysis of biopsy samples demonstrated a significant increase in CD8+ T-cell density in tumors from all 11 patients trea...

biolinerx-to-present-poster-on-economic-model-data-for-aphexda-today-at-ispor-2024
BioLineRx To Present Poster On Economic Mo...
05/06/2024 11:03:27

hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target
HC Wainwright & Co. Reiterates Buy on BioL...
04/17/2024 17:35:07

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

biolinerx-announces-poster-presentation-on-apheresis-center-efficiency-and-cxcr4-antagonists-including-aphexda-at-asfa-2024-annual-meeting-apr-17-19
BioLineRx Announces Poster Presentation On...
04/17/2024 11:02:12

biolinerx-has-drawn-down-the-second-tranche-of-20m-under-its-previously-announced-40m-non-dilutive-debt-financing-agreement-with-funds-and-accounts-managed-by-blackrock
BioLineRx Has Drawn-down The Second Tranch...
04/10/2024 11:14:19

biolinerx-announces-6m-registered-direct-offering-of-75m-ads-and-warrants-to-purchase-up-to-an-aggregate-of-75m-adss-at-a-combined-purchase-price-of-080-per-ads-and-accompanying-warrant
BioLineRx Announces $6M Registered Direct ...
04/01/2024 13:02:55

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical ...

hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target
HC Wainwright & Co. Reiterates Buy on BioL...
03/26/2024 16:12:57

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

bioline-rx-q4-eps-015-beats-022-estimate-sales-480m
BioLine Rx Q4 EPS $(0.15) Beats $(0.22) Es...
03/26/2024 13:28:42

BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
03/26/2024 13:05:52

biolinerx-fy23-total-revenues-48m-eps-006
BioLineRx FY23 Total Revenues $4.8M, EPS $...
03/26/2024 11:02:32

earnings-scheduled-for-march-26-2024
Earnings Scheduled For March 26, 2024
03/26/2024 08:47:27

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

earnings-preview-for-bioline-rx
Earnings Preview For BioLine Rx
03/25/2024 15:02:32

biolinerx-announces-notice-of-allowance-for-us-patent-covering-method-of-manufacturing-motixafortide-bl-8040-suitable-for-large-scale-production-new-patent-when-issued-will-be-valid-until-december-2041
BioLineRx Announces Notice of Allowance fo...
03/04/2024 12:08:04

hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target
HC Wainwright & Co. Reiterates Buy on BioL...
02/29/2024 20:36:19

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION